Aesop Technology, a Taiwan and US-based digital health startup, raised $2.95M in Pre-Series A funding.
The round was led by Taiwania Capital with participation from Colopl Next, 500 Startups, and BE Capital.
The company intends to use the funds to expand into the US market and strengthen the tech team. The company moved their headquarters to San Francisco, launching two apps in the Epic App Market, being accepted into the Mayo Clinic Platform_Accelerate, and publishing a paper with Harvard University last year demonstrating the portability of their model at US hospitals.
Led by CEO Jim Long, and CPO Jeremiah Scholl, Aesop aims to optimize the clinical decision support process with AI-powered technology to improve patient safety and medical coding quality. Started as a university spin-off from Taipei Medical University (TMU), the company leverages the work by Professor Yu Chuan (Jack) Li, the founder and current president of the International Medical Informatics Association, who spent ten years before AESOP working on big data approaches to reduce medication errors. He initially applied the model to launch a product, RxPrime (previously known as MedGuard), that identifies wrong-drug errors. RxPrime detects potential and unexplained errors in prescriptions and provides optimal recommendations from multiple perspectives (department and hospital-wise) based on the patient’s diagnoses, age, and gender. It offers real-time decision support without interfering unnecessarily with the clinical consultation process.
The company also provides DxCode, which acts like a virtual data scientist, mines various medical records to find the proper codes, and speeds up the coding process by providing a whole picture of each inpatient journey to save time going through the complexity of the clinical notes.
FinSMEs
01/09/2022